Biological effects of fulvestrant on estrogen receptor positive human breast cancer: short, medium and long-term effects based on sequential biopsies.

Item

http://www.wikidata.org/entity/Q36933778

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Biological effects of fulvestr ...... based on sequential biopsies.

@en

type

Item

label

Biological effects of fulvestr ...... based on sequential biopsies.

@en

prefLabel

Biological effects of fulvestr ...... based on sequential biopsies.

@en

P1476

Biological effects of fulvestr ...... s based on sequential biopsies

@en

P2093

Amit Agrawal

http://www.w3.org/2001/XMLSchema#string

Eleanor Gutteridge

http://www.w3.org/2001/XMLSchema#string

John F R Robertson

http://www.w3.org/2001/XMLSchema#string

Julia M W Gee

http://www.w3.org/2001/XMLSchema#string

Robert I Nicholson

http://www.w3.org/2001/XMLSchema#string

P2860

Combination anastrozole and fulvestrant in metastatic breast cancer

TIMP1 overexpression mediates resistance of MCF-7 human breast cancer cells to fulvestrant and down-regulates progesterone receptor expression.

Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity

Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal

Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1

Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer.

Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer.

A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer.

Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance.

P304

146-159

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/IJC.29682

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

138

http://www.w3.org/2001/XMLSchema#string

P50

Ian O. Ellis

Kwok-Leung Cheung

P577

2015-07-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

280103628

http://www.w3.org/2001/XMLSchema#string

P698

26178788

http://www.w3.org/2001/XMLSchema#string

P932

4879515

http://www.w3.org/2001/XMLSchema#string